指南与共识生殖医学

多囊卵巢综合征流行病学与表型研究的推荐:雄激素过多与PCOS学会资源

Recommendations for epidemiologic and phenotypic research in polycystic ovary syndrome: an androgen excess and PCOS society resource.
指南 / 共识 · Hum Reprod · 2019-01-01

STUDY QUESTION: What are the best practices for undertaking epidemiologic and phenotypic studies in polycystic ovary syndrome (PCOS)? SUMMARY ANSWER: Best practices for the undertaking of epidemiologic and phenotypic studies in PCOS are outlined.…

要点

  • 研究启动前应明确人群、诊断标准(理想应对齐国际指南)、观察性研究类型及主要和次要终点。
  • 应确定基于稀发排卵、高雄激素和卵巢多囊形态存在与否的四种PCOS表型(A至D)。
  • PCOS流行病学与表型研究需基于准确灵敏的方法检测各特征并明确「正常」定义。

核心结论

  • 工作组概述了PCOS流行病学与表型研究的最佳实践,旨在提高研究的有效性、完整性和可比性。

研究设计与样本

  • AE-PCOS学会成立工作组,根据需要开展针对性文献综述,起草PCOS流行病学与表型研究的指南。
  • 该资源旨在提供研究设计与执行指南、局限性与替代方案及可用的研究方案,并考虑全球视角。

主要发现

  • 高层次推荐包括:研究启动前应解决选择人群和诊断标准(理想应遵循国际指南推荐)、观察性研究类型及主要和次要终点等关键因素。
  • 为评估PCOS的「自然」或真实表型与流行病学,应使用医学偏倚最小、最广泛且最具普遍性的人群,以及最广泛的PCOS定义。
  • 应确定基于稀发排卵、高雄激素和卵巢多囊形态存在与否的四种PCOS表型(表型A至D)。
  • 在流行病学与表型研究中,PCOS的检出依赖于评估疾病各特征所用方法的准确性和敏感性,以及「正常」的定义方式。
  • 尽管可设计尽量减少某些测量(如雄激素水平和/或卵巢超声)的评估算法,但尽可能对所有受试者统一评估所有感兴趣参数更为可取。

关键数值与推荐

  • 推荐将看似无PCOS的受试者(即「非PCOS」)纳入流行病学研究,以建立PCOS各特征的人群特异性正常范围。
  • 在未选择人群中开展PCOS流行病学研究产生的PCOS受试者数量相对有限,难以用于遗传研究;而大型人群流行病学研究可能产生大量未患病个体作为遗传对照。
  • PCOS流行病学研究应建立清晰的治理结构,并应首先告知、教育并吸引目标人群的正式和非正式领导者参与。
  • 研究者在设计研究时应预先确定统计效力,并识别、管理及校正固有偏倚。
  • 疑似PCOS但未/不能完成评估的受试者(即「可能PCOS」)可通过插补法纳入,参照完成研究的相似临床表型受试者赋予其「诊断权重」。

临床怎么用

  • 这些指南应鼓励全球研究者开展亟需的PCOS流行病学研究,提高数据的有效性、完整性和可比性。

局限性

  • 如同所有涉及专家解读经验和已发表数据的报告一样,可能存在固有个人偏倚;本研究通过纳入不同研究领域的专家、与近期国际循证指南保持一致以及获得工作组和AE-PCOS理事会共识批准来最小化这一风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: What are the best practices for undertaking epidemiologic and phenotypic studies in polycystic ovary syndrome (PCOS)? SUMMARY ANSWER: Best practices for the undertaking of epidemiologic and phenotypic studies in PCOS are outlined. WHAT IS KNOWN ALREADY: Currently methodologies used for studies of PCOS epidemiology and phenotypes vary widely, and the comparability of studies is low, reducing the ability to harmonize studies. STUDY DESIGN, SIZE, DURATION: The Androgen Excess and PCOS (AE-PCOS) Society established a Task Force to draft a research resource for epidemiologic and phenotypic studies in PCOS, with the aim of providing guidelines on study design and execution, insights into the limitations and alternatives and protocols to be used, taking into consideration a global perspective. PARTICIPANTS/MATERIALS, SETTING, METHODS: A targeted review of the literature was carried out as necessary. MAIN RESULTS AND THE ROLE OF CHANCE: High level recommendations include the following: (i) Before initiating the study, a number of critical factors should be addressed including selecting the population and diagnostic criteria (which should ideally align with the recommendations of the International Guidelines), the type of observational study to be undertaken and the primary and secondary endpoint(s) of the study.(ii) To assess the 'natural' or true phenotype and epidemiology of PCOS, the least medically biased, broadest and most generalizable population, and the broadest definition of PCOS, should be used.(iii) Four PCOS phenotypes (Phenotypes A through D), based on the presence or absence of three general features (oligo-anovulation, hyperandrogenism and polycystic ovarian morphology), should be ascertained.(iv) In epidemiologic and phenotypic studies, the detection of PCOS rests on the accuracy and sensitivity of the methods used for assessing the individual features of the disorder, and how 'normal' is defined.(v) Although an assessment algorithm that minimizes the use of certain measures (e.g. androgen levels and/or ovarian ultrasonography) can be devised, when possible it is preferable to uniformly assess all subjects for all parameters of interest. UNLABELLED: (vi) The inclusion of subjects in epidemiologic studies who do not appear to have PCOS (i.e. 'non-PCOS') will provide the necessary cohort to establish population-specific normative ranges for the various features of PCOS. (vii) Epidemiologic studies of PCOS in unselected populations will yield relatively limited numbers of PCOS subjects available for genetic study; alternatively, large population-based epidemiologic studies of PCOS will potentially generate large numbers of unaffected individuals that may serve as genetic controls. (viii) Epidemiologic studies of PCOS will benefit from a clear governance structure and should begin by informing, educating and engaging both the formal and informal leaders of the populations targeted for study. (ix) In designing their study investigators should, in advance, establish statistical power and recognize, manage and account for inherent biases. (x) Subjects suspected of having PCOS but who do not/cannot complete their evaluation (i.e. have 'possible PCOS') can be included by imputation, assigning them a 'diagnostic weight' based on those subjects of similar clinical phenotype that have completed the study. (xi) In obtaining, storing and retrieving subject data, subjects should be assessed consecutively using a uniform data collection form; providing as complete and in depth data as possible. (xii) Maintenance of both paper and electronic medical records should focus on ensuring data quality, accuracy and institutional ethical compliance, and familiarity with country-dependent laws, including biobanking-specific laws, tissue laws and research laws. (xiii) In obtaining and biobanking study samples, these should be ideally collected at the time of the first assessment. (xiv) Access to stored data sets should ideally be granted to other bona fide researchers conducting research in the public interest. (xv) SOPs detailing the exact method of each of the activities for handling the data and the samples are necessary to ensure that all methods are performed uniformly. (xvi) Epidemiologic studies of PCOS must be resourced adequately. LIMITATIONS, REASONS FOR CAUTION: As with all reports involving expert interpretation of experiential and published data, inherent individual biases are possible. This risk is minimized in the present study by including experts from varying fields of study, aligning with recent international evidence-based guidelines and obtaining consensus approval of the recommendations from the Task Force and the board of the AE-PCOS. WIDER IMPLICATIONS OF THE FINDINGS: These guidelines should encourage investigators worldwide to undertake much needed epidemiologic studies of PCOS, increasing the validity, integrity and comparability of the data. STUDY FUNDING/COMPETING INTEREST(S): The study received no funding. R.A. serves as consultant for Medtronic, Spruce Biosciences and Ansh Labs; has received research funding from Ferring Pharmaceuticals; and is on the advisory board of Martin Imaging; R.L. has received research funding from MSD Pharmaceuticals; J.L. has received fees and/or grant support from the Dutch Heart Association, The Netherlands Organisation for Health Research and Development (ZonMw), Ferring Pharmaceuticals, Danone, Euroscreen/Ogeda and Titus Health Care; H.T. receives grant funding from the National Health and Medical Research Council; K.K., L.M.-P., S.S.M. and B.O.Y. have no potential conflicts of interest. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Azziz R, Kintziger K, Li R, et al. Recommendations for epidemiologic and phenotypic research in polycystic ovary syndrome: an androgen excess and PCOS society resource. Hum Reprod. 2019. PMID: 31751476. doi:10.1093/humrep/dez185

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。